

## ENVELOPE No. 3 (ECONOMIC OFFER)

### CERTIFICATE OF INCORPORATION OF THE CONTRACT AWARDING COMMITTEE AND THE OPENING OF ENVELOPE NO. 3 WHICH CONTAINS THE PROPOSAL THAT CAN BE ASSESSED THROUGH AUTOMATIC FORMULA RELATING TO THE SERVICE OF DNA AND RNA SEQUENCING AND SPECIALIZED BIOINFORMATIC ANALYSIS FROM TUMOR SAMPLES AND WHOLE BLOOD IN THE FUNDACIÓ HOSPITAL UNIVERSITARI VALL HEBRON - INSTITUT DE RECERCA (VHIR).

Proyecto "PI23/01045", financiado por el Instituto de Salud Carlos III (ISCIII) y cofinanciado por la Unión Europea.



### 2025-031 DNA AND RNA SEQUENCING (PI23/01045)

On 3<sup>rd</sup> of September of 2025 at 10:00 am, on public session, meet the contract awarding committee with the following members:

- **President:** Mr. Xavi Bros Marin, Financial Director of VHIR.
- **Member 1:** Ms. Anna Boix Traserra, Director of Legal Unit of the VHIR.
- **Member 2:** Ms. Montserrat Abad de la Vega, Head of the Accounting and Revenue Unit of the VHIR.
- **Member 3:** Dra. Maria del Mar Garcia Gil, Head of the Post-Award Projects Unit of the VHIR.
- **Member 4:** Dr. Jose Antonio Seoane, Head of the Computational Biology of Cancer Motiu of the VHIO.
- **Secretary:** Ms. Mireia Casamajor Castañeira, Head of the Tenders and Procurement Unit of the VHIR

### Background

**First.-** The purpose of this session is the constitution of the Contract Awarding Committee, the notification of the opening of the envelope relating to the economic offer and the automatic criteria (Envelope No. 3), in order to opt for the award of the contract of service of Next generation sequencing service and data analysis and report including DNA and RNA sequencing from human tumour samples, paired with sequencing of peripheral blood samples as a control sample by the Project PI23/01045 titled "*Plataforma integrativa multiómica para la identificación de biomarcadores predictivos de respuesta a quimioterapia e inmunoterapia en cáncer de mama triple negativo*"

*temprano (PORTRAIT-TNBC)*” of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, by means of announcements to the VHIR Contracting Party Profile and to the Public Contracting Platform of the Generalitat de Catalunya on 16<sup>th</sup> July of 2025.

**Second.-** According to the act of constitution of the Contracting Committee and qualification of the administrative documentation issued on 11<sup>th</sup> August of 2025 the following companies presented themselves and admitted:

- **Hartwig Medical Foundation**
- **Edinburgh Genetics Limited**
- **Sequentia Biotech SL**

**Third.-** Prior to this act, the bidders have been notified through the entity's Contractor Profile, the result of Envelope No. 2, which contain the award criteria to be weighted by a value judgment, the result of which, and according to the technical evaluation report dated on 29<sup>th</sup> of August of 2025, is as follows:

SCORE BOARD							
				56%	14%	30%	
Offers submitted:				Economic Offer	Automatic Evaluation criteria	Value Judgment	
	BI	VAT	TOTAL				TOTAL
Hartwig Medical Foundation						30,00	
Edinburgh Genetics Limited						21,25	
Sequentia Biotech SL						-	

**Fourth.-** In accordance with Clause 12 of the Document of Technical Specifications, on 26<sup>th</sup> August of 2025, a question was sent to bidder company **Sequentia Biotech SL**, requesting it to clarify whether the service related to the sequencing of tumor genomic DNA and normal blood DNA (reference DNA), and the RNA sequencing from the same piece of tumoral tissue will be carried out by the subcontracted company.

After the reply to the clarification within the deadline by the bidder **Sequentia Biotech SL**, the company replied that the service related to the sequencing of tumor genomic DNA and normal blood DNA (reference DNA), and the RNA sequencing from the same piece of tumoral tissue will be carried out by the subcontracted company.

In accordance with the provisions of Clause 22 of the Document of Technical Specifications:

1. *The successful tenderer may only subcontract the partial performance of the contract, which does not constitute the main object of the service tendered for.*

Consequently, it is proposed that company **Sequentia Biotech SL** has been proposed excluded of this bid for non-compliance of the Clause 22 of the Document of Technical Specifications, and without opening its economic offer and criteria that depend on automatic formulas.

**Fifth.-** Before the opening of the first proposal, the Secretary of the Contracting Committee invites the bidders present to express any doubts and to ask for any clarifications they consider appropriate.

**Sixth.-** Afterwards, the opening and review of the proposals made by the companies that have been declared admitted as bidders is carried out:

### Hartwig Medical Foundation

#### A) Financial bid offer (up to 56 points)

Description	Maximum unit price (VAT not included)	Unit Price Offered (VAT not included)	Unit Price Offered (VAT included)
Unit price for sequencing and data analysis of tumor genomic DNA and normal blood DNA (reference DNA), including extraction, sequencing, data analysis and reporting of the results in a manner valid for routine diagnostic purposes.	2.920,00 €	2920 €	Not applicable, invoice will be send without VAT
Unit price for RNA sequencing and reporting from the same piece of tumoral tissue	500,00 €	500 €	Not applicable, invoice will be send without VAT

#### B) Automatic Evaluation Criteria (up to 14 points)

The bidder will indicate with "X" its answer:

Concept	YES	NO	OBSERVATIONS	POINTS
Quality control of the samples by shallow sequencing before full whole genome sequencing.	X		-	05 points

Allow small batches of samples (minimum of 2 samples per batch) to be sent.	X	-	05 points
Turn-around-time of results shorter than 30 days from the reception of the samples (up to 04 points).		Results 23 to 29 days	01 point
		Results 16 to 22 days	02 points
	X	Results 15 days or shorter	04 points

\* The economic offer of each bidder is attached to this document.

## Edinburgh Genetics Limited

### A) Financial bid offer (up to 56 points)

Description	Maximum unit price (VAT not included)	Unit Price Offered (VAT not included)	Unit Price Offered (VAT included)
Unit price for sequencing and data analysis of tumor genomic DNA and normal blood DNA (reference DNA), including extraction, sequencing, data analysis and reporting of the results in a manner valid for routine diagnostic purposes.	2.920,00 €	1900	2299
Unit price for RNA sequencing and reporting from the same piece of tumoral tissue	500,00 €	300	363

### B) Automatic Evaluation Criteria (up to 14 points)

The bidder will indicate with "X" its answer:

Concept	YES	NO	OBSERVATIONS	POINTS
Quality control of the samples by shallow sequencing before full whole genome sequencing.	X		-	05 points

Allow small batches of samples (minimum of 2 samples per batch) to be sent.	X		-	05 points
Turn-around-time of results shorter than 30 days from the reception of the samples (up to 04 points).	X		Results 23 to 29 days	01 point
			Results 16 to 22 days	02 points
			Results 15 days or shorter	04 points

\* The economic offer of each bidder is attached to this document.

That the company has submitted an offer that can be evaluated by means of mathematical formulas or automatic criteria in accordance with the provisions of the bidding document.

### 1. Criteria that can be assessed through [automatic formula](#).....up to 70 points

The following criteria will be evaluated by automatic formula. The award criteria for assessing the contents of [Envelope 3](#) are as follows:

#### 1.1 [FINANCIAL OFFER](#).....(up to 56 points)

It will be valued automatically, in accordance with the following formula:

$$P_v = \left[ 1 - \left( \frac{O_v - O_m}{IL} \right) \times \left( \frac{1}{VP} \right) \right] \times P$$

$P_v$  = Bid Score to Rate

P = Economic criteria points

$O_m$  = Best Offer

$O_v$  = Offer to be Valued

IL = Bid Amount

VP = Weighting Value = 1

The formula will be applied to the value resulting from the following:

- 1) Multiply each unit price offered by the number of samples, which is 50.
- 2) Sum the amount of the previous multiplications.

*\* If after applying the automatic formula to a submitted bid, the resulting value is negative, you will be directly assigned zero (0) points of the economic part.*

### \* Delimitation of allegedly abnormal or disproportionate bids

Since the price offered (Economic Offer) is one of the objective criteria that must serve as the basis for the award, it shall be considered, in accordance with Article 85 of Royal Decree 1098/2001, of October 12, which approves the General Regulations of the Public Administration Contracts Law, as presumably disproportionate or reckless:

1. When, with only one bidder, it is lower than the base bidding budget by more than 25 percentage units.
2. When two bidders participate, the bid that is lower by more than 20 percentage units than the other bid.
3. When there are three bidders, those that are more than 10 percentage units lower than the arithmetic mean of the bids submitted. However, the bid with the highest amount shall be excluded from the calculation of said average when it is more than 10 percentage units higher than said average. In any case, a low bid of more than 25 percentage units shall be considered disproportionate.
4. When there are four or more bidders, those that are more than 10 percentage units lower than the arithmetic mean of the bids submitted. However, if among them there are bids that are more than 10 percentage units higher than said average, a new average shall be calculated only with the bids that are not in the aforementioned situation. In any case, if the number of remaining bids is less than three, the new average shall be calculated on the three lowest bids.

Specifically, under the provisions of Article 149.4 LCSP, the offer will be rejected if it is found to be abnormally low due to non-compliance with the applicable subcontracting obligations, environmental, social or labor, national or international, as well as non-compliance with the sectoral collective agreements in force

## 1.2 AUTOMATIC EVALUATION CRITERIA.....(up to 14 points)

The bidders shall mark the automatic evaluation criteria in Annex No. 1 of the PCAP, which they must provide in [Envelope 3](#):

- Quality control of the samples by shallow sequencing before full whole genome sequencing..... 05 points
  - Allow small batches of samples (minimum of 2 samples per batch) to be sent ..... 05 points
  - Turn-around-time of results shorter than 30 days from the reception of the samples..... up to 04 points
- It will be assessed as follows:
- Turn-around-time of results 23 to 29 days..... 01 point
  - Turn-around-time of results 16 to 22 days..... 02 points
  - Turn-around-time of results 15 days or shorter ..... 04 points

**Seventh.-** The following table of scores, and the consequent ranking of the bidder, has been established:

## SCORE BOARD

56%

14%

30%

Offers submitted:

Economic Offer

Economic Offer

Automatic  
Evaluation  
criteria

Value Judgment

	BI	VAT	TOTAL				TOTAL
Edinburgh Genetics Limited	110.000,00 €	23.100,00 €	133.100,00 €	56,00	11,00	21,25	88,25
Hartwig Medical Foundation	171.000,00 €	35.910,00 €	206.910,00 €	36,02	14,00	30,00	80,02
Sequentia Biotech SL						-	EXCLUDED

(\*) Based on the unit prices quoted.

**Eighth.-** That, in accordance with Clause 9 - AWARD CRITERIA of the Specific Administrative Specifications, the proposal submitted and accepted has been studied, assessed and weighted according to the criteria included in Annex 2 of the aforementioned Specifications, specifically:

“Since the price offered (Economic Offer) is one of the objective criteria that must serve as the basis for the award, it shall be considered, in accordance with Article 85 of Royal Decree 1098/2001, of October 12, which approves the General Regulations of the Public Administration Contracts Law, as

*2. When two bidders participate, the bid that is lower by more than 20 percentage units than the other bid.”*

Therefore, the bid submitted by the tendering company **Hartwig Medical Foundation** does not constitute an allegedly abnormal or disproportionate offer. However, the bid submitted by the bidder **EDINBURGH GENETICS LIMITED** does concur in an allegedly abnormal or disproportionate bid, because they are below 136.800,00 € (excluding VAT).

**Ninth.-** In accordance with Clause 10 of the Specific Administrative Clauses and Article 149.4 of Law 9/2017, of 8 November, on Public Sector Contracts, if the application of these criteria identifies proposal as presumably abnormal or disproportionate, the contracting body will request the affected bidders, in writing, the information and justifications it deems appropriate in relation to the different components of their proposal, a process that must be completed within a maximum period of 5 working days.

Consequently, the Contracting Committee adopts the following:

## AGREEMENTS

**FIRST.- PROPOSE TO EXCLUDE** the bidder company **SEQUENTIA BIOTECH SL** for non-compliance of the Clause 22 of the Document of Technical Specifications.

**SECOND.- TO REQUIRE** the bidding company **EDINBURGH GENETICS LIMITED** to submit the supporting documentation in relation to the components of their presumably abnormal or disproportionate economic offer, which must be completed within a period of 5 working days.

And with no further matters to discuss, this meeting of the Contracting Committee is adjourned.

Barcelona, 3<sup>rd</sup> of September of 2025

**Mr. Xavier Bros Marin**  
President

**Ms. Mireia Casamajor Casteñeira**  
Secretary



## **APPENDIX No. 1**

*Proyecto "PI23/01045", financiado por el Instituto de Salud Carlos III (ISCIII) y cofinanciado por la Unión Europea.*



### **MODEL FOR THE FINANCIAL BID OFFER AND REFERENCES THE ASSESSMENT WHEREOF DEPENDS ON AUTOMATIC FORMULAE**

*Mr / Ms Yun Chan whose address is Pentlands Science Park, UK, from company Edinburgh Genetics Limited the Tax Identity No. whereof is 339658161, having been informed of the invitation to tender and the conditions and requirements for the award of the 2025-031 DNA AND RNA SEQUENCING (PI23/01045), hereby undertakes (in his or her own name or on behalf of the company he or she represents) to carry them out strictly subject to the conditions below:*

*A) Financial bid offer (up to 56 points)*

Description	Maximum unit price (VAT not included)	Unit Price Offered (VAT not included)	Unit Price Offered (VAT included)
<b>Unit price</b> for sequencing and data analysis of tumor genomic DNA and normal blood DNA (reference DNA), including extraction, sequencing, data analysis and reporting of the results in a manner valid for routine diagnostic purposes.	<b>2.920,00 €</b>	1900	2299
<b>Unit price</b> for RNA sequencing and reporting from the same piece of tumoral tissue	<b>500,00 €</b>	300	363

*B) Automatic Evaluation Criteria (up to 14 points)*

The bidder will indicate with "X" its answer:

Concept	YES	NO	OBSERVATIONS	POINTS
Quality control of the samples by shallow sequencing before full whole genome sequencing.	X		-	05 points
Allow small batches of samples (minimum of 2 samples per batch) to be sent.	X		-	05 points
Turn-around-time of results shorter than 30 days from the reception of the samples (up to 04 points).	X		Results 23 to 29 days	01 point
			Results 16 to 22 days	02 points
			Results 15 days or shorter	04 points

Signature and stamp of the bidding company

Yun Hei Chan Yun Hei Chan  
06.08.2025 16:54

Validity of the bid.....4 months

*(bids for a value and/or period of time greater than that of the invitation to tender shall be excluded from the procedure)*

## APPENDIX No. 1

Proyecto "PI23/01045", financiado por el Instituto de Salud Carlos III (ISCIII) y cofinanciado por la Unión Europea.



### MODEL FOR THE FINANCIAL BID OFFER AND REFERENCES THE ASSESSMENT WHEREOF DEPENDS ON AUTOMATIC FORMULAE

Mr Edwin Cuppen whose address is Science Park 408, 1098 XH Amsterdam, from company Hartwig Medical Foundation, the Tax Identity No. whereof is NL855072490B01, having been informed of the invitation to tender and the conditions and requirements for the award of the 2025-031 DNA AND RNA SEQUENCING (PI23/01045), hereby undertakes (in his or her own name or on behalf of the company he or she represents) to carry them out strictly subject to the conditions below:

#### A) Financial bid offer (up to 56 points)

Description	Maximum unit price (VAT not included)	Unit Price Offered (VAT not included)	Unit Price Offered (VAT included)
Unit price for sequencing and data analysis of tumor genomic DNA and normal blood DNA (reference DNA), including extraction, sequencing, data analysis and reporting of the results in a manner valid for routine diagnostic purposes.	2.920,00 €	2920 €	Not applicable, invoice will be send without VAT
Unit price for RNA sequencing and reporting from the same piece of tumoral tissue	500,00 €	500 €	Not applicable, invoice will be send without VAT

#### B) Automatic Evaluation Criteria (up to 14 points)

The bidder will indicate with "X" its answer:

Concept	YES	NO	OBSERVATIONS	POINTS
Quality control of the samples by shallow sequencing before full whole genome sequencing.	x		-	05 points
Allow small batches of samples (minimum of 2 samples per batch) to be sent.	x		-	05 points
Turn-around-time of results shorter than 30 days from the reception of the samples (up to 04 points).			Results 23 to 29 days	01 point
			Results 16 to 22 days	02 points
	x		Results 15 days or shorter	04 points

Signature and stamp of the bidding company

DocuSigned by:  
*Edwin Cuppen*  
3AC4018E9282466...  
Edwin Cuppen

Scientific Director

Hartwig Medical Foundation

01 August 2025

Validity of the bid.....4 months

*(bids for a value and/or period of time greater than that of the invitation to tender shall be excluded from the procedure)*